Briggs Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Briggs Miller has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Albert H. Park
Department of Otolaryngology - Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA
1 shared publication - Bhaskar Birru
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
1 shared publication - Elizabeth M. Arrigali
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
1 shared publication - Joachim G. S. Veit
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
1 shared publication - Matthew A. Firpo
Division of General Surgery University of Utah Utah USA
1 shared publication - Monica Andrea Serban
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA
1 shared publication
Latest Publications
- Open Access
- 23 August 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1037
An Evaluation of the Drug Permeability Properties of Human Cadaveric In Situ Tympanic and Round Window Membranes
It is estimated that hearing loss currently affects more than 1.5 billion people, or approximately 20% of the global population; however, presently, there are no Food and Drug Administration-approved therapeutics or prophylactics for this condition. While continued research on the development of otoprotective drugs to target this clear unmet need is an obvious path, there are numerous challenges to translating promising therapeutic candidates into human clinical testing. The screening of promising drug candidates relies exclusively on preclinical models. Current models do not permit the rapid high-throughput screening of promising drug candidates, and their relevance to clinical scenarios is often ambiguous. With the current study, we seek to understand the drug permeability properties of the cadaveric tympanic and round window membranes with the goal of generating knowledge that could inform the design and/or evaluation of in vitro organotypic models. The development of such models could enable the early high-throughput screening of topical therapeutic candidates and should address some of the limitations of currently used animal models.
- 23 August 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1037
Open AccessAn Evaluation of the Drug Permeability Properties of Human Cadaveric In Situ Tympanic and Round Window Membranes
It is estimated that hearing loss currently affects more than 1.5 billion people, or approximately 20% of the global population; however, presently, there are no Food and Drug Administration-approved therapeutics or prophylactics for this condition. While continued research on the development of otoprotective drugs to target this clear unmet need is an obvious path, there are numerous challenges to translating promising therapeutic candidates into human clinical testing. The screening of promising drug candidates relies exclusively on preclinical models. Current models do not permit the rapid high-throughput screening of promising drug candidates, and their relevance to clinical scenarios is often ambiguous. With the current study, we seek to understand the drug permeability properties of the cadaveric tympanic and round window membranes with the goal of generating knowledge that could inform the design and/or evaluation of in vitro organotypic models. The development of such models could enable the early high-throughput screening of topical therapeutic candidates and should address some of the limitations of currently used animal models.